Adrenocortical carcinoma: No mitotane for low risk of recurrence
University of WürzburgIn 2017, the teams of Massimo Terzolo and Martin Fassnacht published a study in the New England Journal of Medicine that provided evidence for the efficacy of Mitotane in the prevention of recurrence in adrenocortical carcinoma.